Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)

Next Previous
Trial Profile

A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric derisomaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Acronyms PROMISE
  • Sponsors Pharmacosmos

Most Recent Events

  • 19 May 2015 According to a Pharmacosmos media release, results from this trial will be presented at the annual European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
  • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 20 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top